• Media type: E-Article
  • Title: Percutaneous Absorption of Pimecrolimus Is Not Increased in Patients with Moderate to Severe Atopic Dermatitis when Pimecrolimus Cream 1% Is Applied under Occlusion
  • Contributor: Thaçi, Diamant; Kaufmann, Roland; Bieber, Thomas; Hanfland, Julia; Hauffe, Suzanne; Koehne-Voss, Stephan; Waldmeier, Felix
  • Published: S. Karger AG, 2010
  • Published in: Dermatology
  • Extent: 342-351
  • Language: English
  • DOI: 10.1159/000320125
  • ISSN: 1018-8665; 1421-9832
  • Keywords: Dermatology
  • Abstract: <jats:p>&lt;i&gt;Aim:&lt;/i&gt; To evaluate the systemic exposure of pimecrolimus cream 1% applied under occlusion in atopic dermatitis (AD) patients. &lt;i&gt;Methods:&lt;/i&gt; A noncomparative, open-label study conducted in 3 groups of moderate to severe AD patients: A (adults, n = 9), B (adolescents, n = 4) and C (children, n = 6). Pimecrolimus cream 1% was applied twice daily for 8.5 days with overnight occlusion in patients with investigator’s global assessment scores of ≧3 and AD involving at least 30% of their body surface area. Pimecrolimus blood concentrations were analyzed. &lt;i&gt;Results:&lt;/i&gt; The highest pimecrolimus blood concentrations observed in adults, adolescents and children were 1.84, 0.55 and 1.29 ng/ml, respectively. Pimecrolimus blood concentrations and affected body surface area showed no apparent correlation. &lt;i&gt;Conclusion:&lt;/i&gt; No measurable differences were found in pimecrolimus blood concentrations, efficacy and safety profile when pimecrolimus cream 1% was applied under occlusion versus application without occlusion. These findings reflect the high lipophilic properties of pimecrolimus.</jats:p>
  • Description: <jats:p>&lt;i&gt;Aim:&lt;/i&gt; To evaluate the systemic exposure of pimecrolimus cream 1% applied under occlusion in atopic dermatitis (AD) patients. &lt;i&gt;Methods:&lt;/i&gt; A noncomparative, open-label study conducted in 3 groups of moderate to severe AD patients: A (adults, n = 9), B (adolescents, n = 4) and C (children, n = 6). Pimecrolimus cream 1% was applied twice daily for 8.5 days with overnight occlusion in patients with investigator’s global assessment scores of ≧3 and AD involving at least 30% of their body surface area. Pimecrolimus blood concentrations were analyzed. &lt;i&gt;Results:&lt;/i&gt; The highest pimecrolimus blood concentrations observed in adults, adolescents and children were 1.84, 0.55 and 1.29 ng/ml, respectively. Pimecrolimus blood concentrations and affected body surface area showed no apparent correlation. &lt;i&gt;Conclusion:&lt;/i&gt; No measurable differences were found in pimecrolimus blood concentrations, efficacy and safety profile when pimecrolimus cream 1% was applied under occlusion versus application without occlusion. These findings reflect the high lipophilic properties of pimecrolimus.</jats:p>
  • Footnote: